Coherus Oncology (CHRS) Net Cash Flow Growth (1y) (2014 - 2026)
Coherus Oncology (CHRS) Net Cash Flow Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn | 53.46% |
| 10 | Coherus Oncology | 197.78 Mn | 30.73 Mn | 8.50 Mn | 160.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 160.49% |
| Dec 31, 2025 | -151.15% |
| Sep 30, 2025 | -83.94% |
| Jun 30, 2025 | 233.77% |
| Mar 31, 2025 | -127.78% |
| Dec 31, 2024 | 25.03% |
| Sep 30, 2024 | -939.87% |
| Jun 30, 2024 | -277.08% |
| Mar 31, 2024 | 430.96% |
| Dec 31, 2023 | 110.14% |
| Sep 30, 2023 | -35.07% |
| Jun 30, 2023 | 213.11% |
| Mar 31, 2023 | 48.20% |
| Dec 31, 2022 | -494.07% |
| Sep 30, 2022 | -63.25% |
| Jun 30, 2022 | -171.45% |
| Mar 31, 2022 | 67.51% |
| Dec 31, 2021 | -77.22% |
| Sep 30, 2021 | -54.60% |
| Jun 30, 2021 | 123.97% |